KBC Securities - UCB S.A. (UCB) UCB 1H25 conference call feedback

Report

KBC Securities

Jacob Mekhael

UCB 1H25 conference call feedback

UCB reported 1H25 results this morning with a clear beat on CSS. In this note we summarise our key takeaways from the conference call with management.

31/07/2025 1 EN

Underlying

UCB S.A.

UCB is a global biopharmaceutical company focused on severe diseases in two therapeutic areas, namely central nervous system disorders and immunology. In the area of central nervous system disorders, Co. is focused on advanced Parkinson's disease, epilepsy, restless legs syndrome and epilepsy. In the area of immunology disorders, Co. is focused on rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, systemic lupus erythematosus, juvenile idiopathic arthritis, post-menopausal osteoporosis, systemic lupus erythematosus and immunological diseases.

See profile

BE0003739530 Euronext Brussels Belgium

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Jacob Mekhael

Other Reports on these Companies

ING Financial Markets

Benelux Morning Notes

Alfen: Preview - muddling through? Belgian telcos: Competition Authority investigation on Proximus/Orange Belgium MoU. Brunel International: 2Q25 below, 3Q25 outlook cut, cost savings protect FY25 estimates. Euronext: Another record set of results. Fugro: Sharper V-shape? GBL: Weak NAV performance, as expected. KBC Ancora: Cooperative CERA increasing its stake to 51.24%, using excess cash. UCB: Renewed US threats to cut drug prices. Umicore: 1H25 and guide broadly in-line, new ST cathode contract with SK On. Universal Music Group: EBITDA and FCF misses more than offset decen...

9h / 43m 9h / 43m 1 EN

New Street Research

UCB - Still Plenty of Upside – PT up to €270 (BUY, TP €270 [250], 8pgs)

We upgrade our 2026 Bimzelx sales to be €0.9bn higher than consensus with conservative assumptions & and are now 11% above consensus on 2026 group sales & 19% on EBITDA. We upgrade our already above-consensus ‘27 EBITDA by 5%. Using our proprietary product-by-product Contribution Analysis, we show that the gross margin is highly sensitive to Bimzelx growth. We analyse the galvokimig data, which looks very strong Vs Dupi. Whilst UCB pipeline readouts & Moonlake risk will dominate specialists’ thoughts, we expect more interest from generalist investors in the coming months as the growth in conse...

EUR 4378.50

July 31, 2025 July 31, 2025 1 EN

Fugro First look: Weak 1H25 but strong rebound guided for 2H25

Consolidated 1H25 revenue landed at €905m discounting a 15.6% comparable decline. This compares to our revenue of €1016mE and company compiled CSS of €984m. Adjusted EBIT landed at €21m well below our (€75m) and CSS (€61m) estimates. Backlog bottoming out at € 1451m or flat (0.3%) at comparable basis. Ongoing restructuring should save €80-100m annually upon completion and (at the mid point) full year guidance calls for € 189m EBIT25. 2Q EBIT shows first signs of savings kicking in. Leverage well under control at 1.2x. Rating and TP unchanged.

9h / 1m 9h / 1m 1 EN

Guy Sips

Guy Sips

X Fab Silicon Foundries EV Solid set of 2Q25 results, expecting this positive trend to continue in 2H25

X-Fab presented a solid set of 2Q25 results and expect this positive trend to continue in 2H25. We saw an above-average order intake for X-Fab's microsystems business. With the completion of its CapEx program, X-Fab claims it is ideally positioned to grow profitably together with its customers (mainly Melexis). Sufficient capacity is now available for its most popular technologies, suited to address the megatrends of our time, such as the electrification of everything. This will generate high demand in the long term despite a currently reduced visibility. 3Q25 revenue is expected to come in...

10h 10h 1 EN

Jacob Mekhael

Jacob Mekhael

Sequana Medical Publishes alfapump case report in journal, US launch on track

Sequana announced the publication of a case report of a patient in the POSEIDON study that underwent a successful robotic hernia repair following control of their ascites with the alfapump. Looking ahead, the US commercial launch remains on track for this quarter. Should the company demonstrate initial commercial traction during the soft launch phase, this could trigger additional investor interest to fund the company into the broader launch, which is expected in 2Q26. We reiterate our € 5 TP and Buy rating.

10h / 7m 10h / 7m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

UCB 1H25 conference call feedback

We are a financial services provider for several types of professional clients, each with distinct needs.

Benelux Morning Notes

UCB - Still Plenty of Upside – PT up to €270 (BUY, TP €270 [250], 8pgs)

Fugro First look: Weak 1H25 but strong rebound guided for 2H25

X Fab Silicon Foundries EV Solid set of 2Q25 results, expecting this positive trend to continue in 2H25

Sequana Medical Publishes alfapump case report in journal, US launch on track

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe